Adaptive Biotechnologies Corp
NASDAQ:ADPT
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.335
6.49
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one ADPT stock under the Base Case scenario is 6.89 USD. Compared to the current market price of 4.69 USD, Adaptive Biotechnologies Corp is Undervalued by 32%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Adaptive Biotechnologies Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for ADPT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Adaptive Biotechnologies Corp
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Adaptive Biotechnologies Corp
Balance Sheet Decomposition
Adaptive Biotechnologies Corp
Current Assets | 308.3m |
Cash & Short-Term Investments | 243.3m |
Receivables | 40.8m |
Other Current Assets | 24.2m |
Non-Current Assets | 250.2m |
Long-Term Investments | 23.9m |
PP&E | 97.8m |
Intangibles | 122.8m |
Other Non-Current Assets | 5.6m |
Current Liabilities | 87.6m |
Accounts Payable | 7.4m |
Accrued Liabilities | 28.4m |
Other Current Liabilities | 51.9m |
Non-Current Liabilities | 247.1m |
Long-Term Debt | 132.7m |
Other Non-Current Liabilities | 114.4m |
Earnings Waterfall
Adaptive Biotechnologies Corp
Revenue
|
177.3m
USD
|
Cost of Revenue
|
-73.7m
USD
|
Gross Profit
|
103.6m
USD
|
Operating Expenses
|
-270.8m
USD
|
Operating Income
|
-167.1m
USD
|
Other Expenses
|
-28.1m
USD
|
Net Income
|
-195.2m
USD
|
Free Cash Flow Analysis
Adaptive Biotechnologies Corp
USD | |
Free Cash Flow | USD |
ADPT Profitability Score
Profitability Due Diligence
Adaptive Biotechnologies Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Adaptive Biotechnologies Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
ADPT Solvency Score
Solvency Due Diligence
Adaptive Biotechnologies Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Score
Adaptive Biotechnologies Corp's solvency score is 41/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ADPT Price Targets Summary
Adaptive Biotechnologies Corp
According to Wall Street analysts, the average 1-year price target for ADPT is 7.57 USD with a low forecast of 5.56 USD and a high forecast of 10.5 USD.
Dividends
Current shareholder yield for ADPT is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
ADPT Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. The company is headquartered in Seattle, Washington and currently employs 858 full-time employees. The company went IPO on 2019-06-27. The firm is focused on using the biology of the adaptive immune system to develop the diagnosis and treatment of disease. Its immune medicine platform combines a suite of chemistry, biology and machine learning to generate clinical immunomics data to decode the adaptive immune system. Its commercial research products include immunoSEQ and immunoSEQ T-MAP. immunoSEQ utilizes bias-controlled polymerase chain reaction (PCR) to sequence immune receptors from deoxyribonucleic (DNA). Its clonoSEQ diagnostic test detects and monitors the number of cancer cells that are present in a patient’s body during and after treatment, known as minimal residual disease (MRD). The company uses its T cell receptor (TCR)-Antigen Map to develop research solutions and diagnostic products, such as immunoSEQ T-MAP and T-Detect. The company also focuses on developing immune-mediated therapies in oncology and other disease areas.
Contact
IPO
Employees
Officers
The intrinsic value of one ADPT stock under the Base Case scenario is 6.89 USD.
Compared to the current market price of 4.69 USD, Adaptive Biotechnologies Corp is Undervalued by 32%.